secwatch.observer — SEC 8-K summary
======================================

Issuer:     IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
CIK:        0001425205
Form:       8-K
Filed at:   2024-03-04T23:59:59+00:00
Accession:  0001104659-24-030249
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA lifts clinical hold on Iovance's IOV-LUN-202 NSCLC trial; enrollment to resume
--------------------------------------------------------------------------------

- FDA cleared Iovance to resume patient enrollment in registrational IOV-LUN-202 trial for LN-145 TIL therapy in NSCLC.
- Additional safety and monitoring measures developed with FDA and independent data monitoring committee.
- Iovance expects to complete enrollment of ~120 patients in registrational cohorts by 2025.
- Updated Nov 2023 data showed 71% of confirmed responders had duration of response >6 months.
- Initial preliminary data from July 2023 supported durable responses over available second-line chemotherapies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1425205/000110465924030249/0001104659-24-030249-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1425205/000110465924030249/tm247846d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-030249

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer